Sponsor or institution
Clinical trials and research at Beijing InnoCare Pharma Tech Co., Ltd.
As of November 12, 2026, Find a Trial lists 20 clinical trials run by Beijing InnoCare Pharma Tech Co., Ltd. that are recruiting, at sites in 6 countries (most in China (20), United States (2), Australia (1)). By phase: Phase 2 (6), Phase 3 (4), Phase 1 (4), Phase 2/3 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 20Clinical trials
- 6Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| ICP-B208 in people with advanced solid tumors | Phase 1/2 | Beijing, Beijing Municipality and 2 other locations | Recruiting | Jun 1, 2026 |
| Testing ICP-538 safety and dosing in healthy adults. | Phase 1 | Beijing, Beijing Municipality | Recruiting | Apr 16, 2026 |
| ICP-488 for Cutaneous Lupus Erythematosus: a 2nd phase study to test safety and efficacy | Phase 2 | Hefei, Anhui and 26 other locations | Recruiting | Feb 27, 2026 |
| ICP-332 for adults with moderate to severe chronic spontaneous urticaria not controlled by antihistamines | Phase 2/3 | Bengbu, Anhui and 29 other locations | Recruiting | Jan 30, 2026 |
| ICP-332 versus placebo for moderate-to-severe plaque psoriasis | Phase 2 | Shanghai, Shanghai Municipality | Recruiting | Nov 26, 2025 |
| ICP-332 for adults with prurigo nodularis | Phase 2 | Birmingham, Alabama and 42 other locations | Recruiting | Nov 19, 2025 |
| ICP-248 treatment for relapsed or refractory mantle cell lymphoma | Phase 2 | Hefei, Anhui and 28 other locations | Recruiting | Jul 24, 2025 |
| ICP-332 treatment for non-segmental vitiligo | Phase 2/3 | Wuhu, Anhui and 44 other locations | Recruiting | Jul 2, 2025 |
| Evaluating ICP-488 for treating moderate to severe plaque psoriasis | Phase 3 | Hefei, Anhui and 45 other locations | Recruiting | Feb 24, 2025 |
| Evaluating ICP-332 for treating moderate to severe atopic dermatitis | Phase 3 | Hefei, Anhui and 61 other locations | Recruiting | Jan 15, 2025 |
All recruiting trials (20)
-
ICP-B208 in people with advanced solid tumors
This trial tests ICP-B208 to see if it is safe and can help people with unresectable or metastatic solid tumors who have already tried other treatments.
-
Testing ICP-538 safety and dosing in healthy adults.
This study will test single and multiple doses of the experimental tablet ICP-538 versus placebo to see if it is safe and how the body absorbs and clears it in healthy adults.
-
ICP-488 for Cutaneous Lupus Erythematosus: a 2nd phase study to test safety and efficacy
This phase II study tests ICP-488 versus placebo in adults with cutaneous lupus erythematosus to see if it helps skin symptoms while checking safety.
-
ICP-332 for adults with moderate to severe chronic spontaneous urticaria not controlled by antihistamines
This study tests whether ICP-332 tablets can reduce hives and itching in adults (18–75) with moderate to severe chronic spontaneous urticaria that is not controlled by second-generation H1-antihistamines.
-
ICP-332 versus placebo for moderate-to-severe plaque psoriasis
This will test whether ICP-332 helps adults with moderate-to-severe plaque psoriasis compared with a placebo.
-
ICP-332 for adults with prurigo nodularis
This will test whether ICP-332 can reduce severe itching and the nodules in adults with prurigo nodularis.
-
ICP-248 treatment for relapsed or refractory mantle cell lymphoma
This will try ICP-248 in adults whose mantle cell lymphoma has returned or not responded after prior anti-CD20 and BTK inhibitor therapies.
-
ICP-332 treatment for non-segmental vitiligo
This trial will test whether oral ICP-332 tablets help people with non-segmental vitiligo (including adolescents in the Phase III part) who have at least 5% body surface area affected and facial involvement regain skin pigment better than placebo.
-
Evaluating ICP-488 for treating moderate to severe plaque psoriasis
This study is testing a new medication called ICP-488 to see if it can help adults in China with moderate to severe plaque psoriasis feel better and improve their skin health.
-
Evaluating ICP-332 for treating moderate to severe atopic dermatitis
This study is testing a new oral medication called ICP-332 to see if it can help people with moderate to severe atopic dermatitis who haven't found relief from other treatments.
-
Combining ICP-248 with Azacitidine for treating Acute Myelogenous Leukemia
This study is testing whether a new drug called ICP-248, when combined with azacitidine, can safely help people with Acute Myelogenous Leukemia feel better and improve their treatment outcomes.
-
Combining Tafasitamab and Lenalidomide with Gemcitabine and Oxaliplatin for treating relapsed DLBCL
This study is testing a new combination of medications for people with relapsed DLBCL to see if it works better than the standard treatment.
-
Combining ICP-248 and Orelabrutinib for treating chronic lymphocytic leukemia
This study is testing if combining two medications, ICP-248 and Orelabrutinib, can help people with newly diagnosed chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and improve their treatment results.
-
Combining Orelabrutinib with Lenalidomide and Rituximab for treating relapsed Marginal Zone Lymphoma
This study is testing if adding a new drug called Orelabrutinib to the standard treatment of Lenalidomide and Rituximab can help people with relapsed Marginal Zone Lymphoma feel better and improve their outcomes.
-
Evaluating ICP-723 for advanced solid tumors and CNS tumors with NTRK fusions
This study is testing a new drug called ICP-723 to see if it can help people with advanced solid tumors or brain tumors that have specific gene changes.
-
Evaluating ICP-248 for treating mature B-cell cancers
This study is testing a new treatment called ICP-248, alone and with another drug, to see if it can help people with mature B-cell cancers.
-
Evaluating CM369 for advanced solid tumors and blood cancers
This study is testing a new treatment called CM369 to see if it is safe and effective for people with advanced solid tumors and blood cancers.
-
Evaluating ICP-192 for patients with advanced intrahepatic cholangiocarcinoma
This study is testing a new drug called ICP-192 to see if it can help people with advanced liver cancer that hasn't improved with other treatments.
-
Combining Tafasitamab and Lenalidomide for treating relapsed DLBCL
This study is testing if combining Tafasitamab and Lenalidomide can help people with relapsed or hard-to-treat Diffuse Large B-Cell Lymphoma feel better.
-
Testing ICP-723 for advanced solid tumors
This study is testing a new drug called ICP-723 to see how safe it is and how well it works for people with advanced solid tumors that can't be removed by surgery.
Quick answers
How many clinical trials run by Beijing InnoCare Pharma Tech Co., Ltd. are recruiting right now?
20, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 6 countries. The most sites are in China (20 trials), United States (2 trials), Australia (1 trial), France (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 6, Phase 3: 4, Phase 1: 4, Phase 2/3: 3. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.